These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 34842714)

  • 21. Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.
    Breyer MK; Breyer-Kohansal R; Hartl S; Kundi M; Weseslindtner L; Stiasny K; Puchhammer-Stöckl E; Schrott A; Födinger M; Binder M; Fiedler M; Wouters EFM; Burghuber OC
    Sci Rep; 2021 May; 11(1):10158. PubMed ID: 33980950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review.
    Oran DP; Topol EJ
    Ann Intern Med; 2021 May; 174(5):655-662. PubMed ID: 33481642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parental Coronavirus Disease 2019 Testing of Hospitalized Children: Rethinking Infection Control in a Pandemic.
    Hassoun A; Prasad N; Pugh S; Merced I; Abularrage J; Sharma M
    J Pediatric Infect Dis Soc; 2020 Nov; 9(5):564-565. PubMed ID: 32856705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.
    Levorson RE; Christian E; Hunter B; Sayal J; Sun J; Bruce SA; Garofalo S; Southerland M; Ho S; Levy S; Defillipi C; Peake L; Place FC; Hourigan SK
    PLoS One; 2021; 16(11):e0259823. PubMed ID: 34748615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review.
    Byambasuren O; Dobler CC; Bell K; Rojas DP; Clark J; McLaws ML; Glasziou P
    PLoS One; 2021; 16(4):e0248946. PubMed ID: 33798211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National cross-sectional survey of 1.14 million NHS staff SARS-CoV-2 serology tests: a comparison of NHS staff with regional community seroconversion rates.
    Coltart CEM; Wells D; Sutherland E; Fowler A
    BMJ Open; 2021 Jul; 11(7):e049703. PubMed ID: 34257096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys.
    Kshatri JS; Bhattacharya D; Praharaj I; Mansingh A; Parai D; Kanungo S; Palo SK; Giri S; Pattnaik M; Barik SR; Dash GC; Choudhary HR; Turuk J; Mandal NN; Pati S
    Epidemiol Infect; 2021 Apr; 149():e139. PubMed ID: 33902776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Rates of SARS-CoV-2 Family Transmission in Children of Healthcare Workers During the First Pandemic Wave in Madrid, Spain: Serologic Study.
    Méndez-Echevarría A; Sainz T; de Felipe B; Alcolea S; Olbrich P; Goycochea-Valdivia WA; Escosa-García L; Cobo L; Calvo C; Neth O
    Pediatr Infect Dis J; 2021 May; 40(5):e185-e188. PubMed ID: 33591078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
    Stringhini S; Zaballa ME; Pullen N; Perez-Saez J; de Mestral C; Loizeau AJ; Lamour J; Pennacchio F; Wisniak A; Dumont R; Baysson H; Richard V; Lorthe E; Semaani C; Balavoine JF; Pittet D; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe K; Kaiser L; Guessous I;
    Euro Surveill; 2021 Oct; 26(43):. PubMed ID: 34713799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
    Stringhini S; Wisniak A; Piumatti G; Azman AS; Lauer SA; Baysson H; De Ridder D; Petrovic D; Schrempft S; Marcus K; Yerly S; Arm Vernez I; Keiser O; Hurst S; Posfay-Barbe KM; Trono D; Pittet D; Gétaz L; Chappuis F; Eckerle I; Vuilleumier N; Meyer B; Flahault A; Kaiser L; Guessous I
    Lancet; 2020 Aug; 396(10247):313-319. PubMed ID: 32534626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Seroprevalence among a Southern U.S. Population Indicates Limited Asymptomatic Spread under Physical Distancing Measures.
    Barzin A; Schmitz JL; Rosin S; Sirpal R; Almond M; Robinette C; Wells S; Hudgens M; Olshan A; Deen S; Krejci P; Quackenbush E; Chronowski K; Cornaby C; Goins J; Butler L; Aucoin J; Boyer K; Faulk J; Alston-Johnson D; Page C; Zhou Y; Fiscus L; Damania B; Dittmer DP; Peden DB
    mBio; 2020 Sep; 11(5):. PubMed ID: 32994333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surveillance of Acute SARS-CoV-2 Infections in School Children and Point-Prevalence During a Time of High Community Transmission in Switzerland.
    Kriemler S; Ulyte A; Ammann P; Peralta GP; Berger C; Puhan MA; Radtke T
    Front Pediatr; 2021; 9():645577. PubMed ID: 33796490
    [No Abstract]   [Full Text] [Related]  

  • 33. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
    Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
    Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroprevalence of SARS-CoV-2 antibodies in children of United Kingdom healthcare workers: a prospective multicentre cohort study protocol.
    Corr M; Christie S; Watson C; Maney J; Fairley D; Ladhani SN; Lyttle MD; McFetridge L; Mitchell H; Shields MD; McGinn C; McKenna J; Mallett P; Ferris K; Rowe-Setz G; Moore R; Foster S; Evans J; Waterfield T
    BMJ Open; 2020 Nov; 10(11):e041661. PubMed ID: 33444212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.
    Iruretagoyena M; Vial MR; Spencer-Sandino M; Gaete P; Peters A; Delgado I; Perez I; Calderon C; Porte L; Legarraga P; Anderson A; Aguilera X; Vial P; Weitzel T; Munita JM
    BMC Infect Dis; 2021 May; 21(1):478. PubMed ID: 34039287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut.
    Papasavas P; Olugbile S; Wu U; Robinson K; Roberts AL; O'Sullivan DM; McLaughlin T; Mather JF; Steinberg AC; Orlando R; Kumar A
    J Hosp Infect; 2021 Aug; 114():117-125. PubMed ID: 33930487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich.
    Pritsch M; Radon K; Bakuli A; Le Gleut R; Olbrich L; Guggenbüehl Noller JM; Saathoff E; Castelletti N; Garí M; Pütz P; Schälte Y; Frahnow T; Wölfel R; Rothe C; Pletschette M; Metaxa D; Forster F; Thiel V; Rieß F; Diefenbach MN; Fröschl G; Bruger J; Winter S; Frese J; Puchinger K; Brand I; Kroidl I; Hasenauer J; Fuchs C; Wieser A; Hoelscher M; On Behalf Of The KoCo Study Group
    Int J Environ Res Public Health; 2021 Mar; 18(7):. PubMed ID: 33808249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nationwide seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in South Korea: a cross-sectional study.
    Nah EH; Cho S; Park H; Hwang I; Cho HI
    BMJ Open; 2021 Apr; 11(4):e049837. PubMed ID: 33895722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Serologic Changes of IgG and IgM Antibodies Associated with SARS-COV-2 in Cancer Patients: A Cohort Seroprevalence Study.
    Arab M; Noei Teymoordash S; Talayeh M; Ghavami B; Javadi A; Nouri B
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1667-1670. PubMed ID: 34181320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.